Autolus Therapeutics (AUTL) and Its Peers Head to Head Analysis

Autolus Therapeutics (NASDAQ:AUTL) is one of 844 public companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Autolus Therapeutics to similar companies based on the strength of its institutional ownership, profitability, risk, valuation, analyst recommendations, dividends and earnings.

Analyst Recommendations

This is a summary of current ratings for Autolus Therapeutics and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1	1	3	2	2.86
Autolus Therapeutics Competitors	9800	15081	45386	1576	2.54

Autolus Therapeutics currently has a consensus price target of $10.00, suggesting a potential upside of 693.65%. As a group, “Biotechnology” companies have a potential upside of 104.63%. Given Autolus Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Autolus Therapeutics is more favorable than its rivals.

Insider & Institutional Ownership

72.8% of Autolus Therapeutics shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Autolus Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Autolus Therapeutics	$75.39 million	-$287.53 million	-1.19
Autolus Therapeutics Competitors	$723.49 million	$12.98 million	-10.84

Autolus Therapeutics’ rivals have higher revenue and earnings than Autolus Therapeutics. Autolus Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Volatility and Risk

Autolus Therapeutics has a beta of 2.32, suggesting that its stock price is 132% more volatile than the S&P 500. Comparatively, Autolus Therapeutics’ rivals have a beta of 1.15, suggesting that their average stock price is 15% more volatile than the S&P 500.

Profitability

This table compares Autolus Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-238.66%	-178.66%	-49.34%
Autolus Therapeutics Competitors	-12,359.35%	-203.09%	-30.93%

Summary

Autolus Therapeutics beats its rivals on 9 of the 13 factors compared.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.